title: Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy.
abstract: When severely immunodeficient HIV/HCV co-infected patients are treated with antiretroviral therapy, it is important to know whether HCV-specific antibody responses recover and whether antibody profiles predict the occurrence of HCV-associated immune restoration disease (IRD). In 50 HIV/HCV co-infected patients, we found that antibody reactivity and titres of neutralising antibodies (nAb) to JFH-1 (HCV genotype 2a virus) increased over 48 weeks of therapy. Development of HCV IRD was associated with elevated reactivity to JFH-1 before and during the first 12 weeks of therapy. Individual analyses of HCV IRD and non-HCV IRD patients revealed a lack of an association between nAb responses and HCV viral loads. These results showed that increased HCV-specific antibody levels during therapy were associated with CD4(+) T-cell recovery. Whilst genotype cross-reactive antibody responses may identify co-infected patients at risk of developing HCV IRD, neutralising antibodies to JFH-1 were not involved in suppression of HCV replication during therapy.
authors.affiliation: School of Pathology and Laboratory Medicine, University of Western Australia, Australia; Department of Microbiology and Infectious Disease, Royal Perth Hospital, Australia. Electronic address: silvia.lee@uwa.edu.au.
authors.forename: Silvia
authors.initials: S
authors.lastname: Lee
authors.affiliation: Institute of Human Virology and Cancer Biology, University of Indonesia, Indonesia.
authors.forename: Henny
authors.initials: H
authors.lastname: Saraswati
authors.affiliation: School of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Indonesia.
authors.forename: Evy
authors.initials: E
authors.lastname: Yunihastuti
authors.affiliation: School of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Indonesia.
authors.forename: Rino
authors.initials: R
authors.lastname: Gani
authors.affiliation: School of Pathology and Laboratory Medicine, University of Western Australia, Australia.
authors.forename: Patricia
authors.initials: P
authors.lastname: Price
mesh_terms: D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000276:immunology; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002460:Cell Line; D060085:Coinfection; D003429:Cross Reactions / Q000276:immunology; D005838:Genotype; D006678:HIV / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D016174:Hepacivirus / Q000235:genetics* / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D018937:Hepatitis C Antibodies / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D019562:Viral Load; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D018937:Hepatitis C Antibodies
keywords: Antiretroviral therapy; Genotype cross-reactive neutralising antibody; HCV; HIV